News | Computer-Aided Detection Software | April 11, 2017

Parascript and Volpara Establish Partnership for Improved Early Cancer Detection

Companies combine automated breast density assessment with computer-aided detection to help find breast cancers earlier

Parascript and Volpara Establish Partnership for Improved Early Cancer Detection

April 11, 2017 — Parascript LLC announced a new partnership with Volpara Solutions, creator of Volpara Density automated breast density assessment software. Independent research has associated an increased risk of cancer for patients with high breast density, which can also make cancer harder to detect on conventional mammograms. Together, Parascript AccuDetect CAD (computer-aided detection) and VolparaDensity provide complementary early cancer detection solutions.

Screening patients with dense breasts can pose additional challenges to healthcare providers since dense tissue has been shown to hide tumors and is associated with an increased risk of not only breast cancer, but more aggressive breast cancer. Accurate automated measurement of volumetric fibroglandular breast density assists radiologists in each patient’s personalized screening and decision making for additional diagnostics. Correctly identifying patients at low risk is also important to avoid unnecessary tests, because it can be stressful and costly for patients called back for further assessment. Parascript AccuDetect CAD, powered by deep learning, uses multiple independent cancer detection algorithms and a unique patented voting methodology to combine its findings. Comparing the results of the multiple image recognition processes allows for improved sensitivity and reduced false-positive rates.

In a study by the Karolinska Institute in Sweden of 41,102 women from KARMA (KARolinska MAmmography project for risk prediction of breast cancer) that looked at mammography screenings and clinical mammography at four hospitals in Sweden, VolparaDensity was validated across multiple mammography vendor platforms. This study concluded that automated measurement of volumetric mammographic density using VolparaDensity was a promising tool for breast cancer risk assessment.

In addition to more accurate detection, AccuDetect processes images more rapidly, which can improve response time to patients. AccuDetect CAD processes at 11 seconds per image, the fastest of all available U.S. Food and Drug Administration (FDA)-approved CAD systems, according to the company. The average CAD system takes 30 seconds or more to process a single image. AccuDetect CAD also supports early, more accurate detection, delivering high performance on dense and extremely dense breasts, according to a clinical study reported in Clinical Imaging (M. Lobbes et al., Clinical Imaging 37 (2013) 283-288).

Parascript and Volpara both exhibited at the Society for Breast Imaging (SBI) Breast Imaging Symposium in Los Angeles, held on April 6-8, 2017, and provided product demonstrations.

For more information: www.volparasolutions.com, www.parascript.com

Related Content

Therapixel Wins the Digital Mammography Challenge
News | Mammography | June 23, 2017
June 23, 2017 — French radiology technology company Therapixel was recently named the winner of the Digital Mammograp
ClearRead CT Nearing 50 Installations Milestone
News | Computed Tomography (CT) | June 22, 2017
June 22, 2017 — Riverain Technologies announced that it is now processing data from nearly 50...
MRI Plus Mammography Improves Detection of New Breast Cancer After Surgery
News | Breast Imaging | June 22, 2017
A new article published by JAMA Oncology compares outcomes for combined mammography and magnetic resonance imaging (MRI...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
ABS Clinical Director Alexandra Valencia, M.D.,  and consultant radiographer Gillian Clark using Insignia.

ABS Clinical Director Alexandra Valencia, M.D.,  and consultant radiographer Gillian Clark using Insignia.

News | Breast Imaging | June 12, 2017
ABS, one of the largest breast departments in the country, first signed with Insignia in 2010, and have confirmed a...
mammogram

Photo courtesy of Barco

News | Mammography | June 08, 2017
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are...
OCM images

These are sample OCM images (first row) and corresponding histology images (second row) of human breast tissue. The ground truth labels for the tissue type of these images are: (a) carcinoma, (b) lobule, (c) stroma, (d) adipose. Image courtesy of Sunhua Wan, Hsiang-Chieh Lee, Xiaolei Huang, Ting Xu, Tao Xu, Xianxu Zeng, Zhan Zhang, Yuri Sheikine, James L. Connolly, James G. Fujimoto, Chao Zhou

News | Clinical Study | June 07, 2017
According to a recent study, one in four women with breast cancer who opt for a breast-saving lumpectomy will need a...
News | Mammography | June 07, 2017
Hologic, Inc. announced that the Genius 3D Mammography exam is now the only mammogram that is FDA-approved as superior...
Feature | Women's Health | June 06, 2017 | By David A. Strahle, M.D.
Editor’s note: In this article, David A. Strahle, M.D., candidly shares how and why he and his team became involved...
breast tomosynthesis
News | Breast Imaging | June 06, 2017
Researchers at two leading U.S. breast centers recently completed a study which explored whether women attending...
Overlay Init